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Abstract 
Aims 
The prognostic impact of chronic total coronary occlusion (CTO) on implantable cardioverter-
defibrillator (ICD) recipients remains unclear. 
Methods and Results 
Eighty-four consecutive patients with ischemic heart disease who received ICD therapy for 
primary or secondary prevention were analyzed. We investigated all-cause mortality and major 
adverse cardiac events (MACEs) including cardiac death, appropriate device therapy, 
hospitalization for heart failure, and ventricular assist device implantation. Of the study patients 
(mean age 70 ± 8 years; 86% men), 34 (40%) had CTO. There were no significant differences in 
age, left ventricular ejection fraction (LVEF), NYHA functional class III or IV status, and 
proportion who underwent secondary prevention between patients with CTO (CTO group) and 
without CTO (non-CTO group). During a median follow-up of 3.8 years (interquartile range 2.7 
to 5.4 years), the CTO group tended to have a higher MACE rate (log-rank P=0.054) than the 
non-CTO group. Within the CTO group, there was no difference in the MACE rate between 
patients with and without viable myocardium. In patients with ICD for secondary prevention 
(n=47), 16 patients (34%) with CTO had a higher MACE rate than patients without CTO (log-
rank P<0.01). Cox proportional hazards regression analysis showed that the presence of CTO, but 
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not LVEF, was associated with a higher MACE rate. Multivariate analysis showed that the 
presence of CTO was a predictor of MACE (P<0.05). 
Conclusion 
In patients with ischemic heart disease receiving ICD implantation, the presence of CTO has an 
adverse impact on long-term prognosis, especially as secondary prevention. 
 
Keywords: Chronic total occlusion, implantable cardioverter-defibrillator, ischemic heart disease, 
revascularization, myocardial viability 
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Introduction 
In ischemic heart disease (IHD), left ventricular (LV) function, as reflected by ejection fraction 
(EF), is known to be a predictive factor for mortality and ventricular arrhythmic events. On the 
basis of the previous randomized trial1,2, cardioverter-defibrillator (ICD) implantation may have 
benefits in terms of both primary and secondary prevention against sudden cardiac death in 
patients with prior myocardial infarction and a history of ventricular fibrillation, sustained 
ventricular tachycardia, or non-sustained ventricular tachycardia with syncope and severe LV 
dysfunction. International guidelines recommend ICD implantation for these particular patients 
as a class I recommendation.3,4 
The SOLVD trial showed that revascularization significantly decreases the risk of 
sudden cardiac death in patients with coronary artery disease and LVEF <35%.5 A meta-analysis 
showed that revascularization could potentially improve survival in patients with low LVEF and 
viable myocardium, but not in those without viable myocardium.6 Indeed, the 2015 guidelines of 
the European Society of Cardiology recommended that patients with ischemic LV dysfunction 
(LVEF <35%) and indications for primary preventive ICD implantation should be evaluated for 
residual ischemia and potential revascularization targets because of the protective effect of 
revascularization against ventricular arrhythmias.3 
The presence of chronic total coronary occlusion (CTO) is associated with long-term 
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mortality and further deterioration of LVEF. Recent studies have reported that patients who 
underwent successful percutaneous coronary intervention (PCI) for CTO have better prognosis 
than those who did not.7 One study reported PCI has positive effects on LV remodeling and LVEF 
for up to 3 years in the CTO perfusion territory.8 The COURAGE trial found that the prognostic 
impact of revascularization with PCI is enhanced if there is more than 5% reduction in ischemia.9 
Myocardial viability is indeed important when considering patient prognosis and indications for 
revascularization. However, in high-risk IHD patients with implanted ICDs, the association 
between CTO and/or myocardial viability with cardiac events remains to be fully investigated. 
Therefore, the purpose of the present study was to evaluate the long-term prognostic 
impact of CTO in IHD patients with left ventricular dysfunction who received ICD for primary 
or secondary prevention. 
 
Methods 
Study patients and outcome measures 
All patients with IHD who received ICDs for primary or secondary prevention at the National 
Cerebral and Cardiovascular Center in Japan between 2007 and 2012 were included in this study. 
IHD was defined as myocardial dysfunction secondary to occlusive or obstructive coronary artery 
disease. Baseline clinical data were obtained retrospectively from medical records. We 
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categorized patients into two groups according to the presence or absence of CTO on the basis of 
findings on coronary angiography performed most recently before ICD implantation. The 
presence of CTO was defined as total occlusion of a major epicardial artery with Thrombolysis 
in Myocardial Infarction (TIMI) flow grade 0 for more than 3 months with or without retrograde 
filling through collateral vessels. Occluded vessels that were surgically revascularized were not 
considered to have CTO. Subgroup analysis was also performed, stratified by primary or 
secondary prevention, and the presence of viable myocardium in the CTO area. 
The viability of the myocardium in the CTO area was determined by the presence of 
radionuclide uptake more than 50% of that in normal segments on myocardial scintigraphy, or by 
the absence of a thinned scar, dyskinesis, or left ventricular wall thickness greater than 6 mm 
during diastole based on echocardiography.10, 11 Myocardial scintigraphy and echocardiography 
images were assessed by two expert cardiologists. LVEF was calculated with echocardiography 
using the biplane Simpson method. Estimated glomerular filtration rate was obtained using the 
formula previously reported by the Japan Association of Chronic Kidney Disease Initiative.12 
Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate less than 60 
mL/min.  
 
ICD implantation and data analysis 
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In the present study population, indications for ICD, including a cardiac resynchronization 
therapy defibrillator (CRT-D), were based on guidelines.3, 4 All patients received a multifunctional 
single-chamber ICD, dual-chamber ICD, or CRT-D. All defibrillator systems were implanted 
transvenously without epicardial systems. Testing for the sensing, pacing, and defibrillation 
thresholds was performed during the implantation procedure and 3 to 5 days after implantation. 
The records for ICD follow-up visits every 3 to 4 months were reviewed. Appropriate 
ICD therapy was detected from generator interrogation during an outpatient visit or hospital 
admission by expert electrophysiologists. Dates of death, admissions for heart failure, ICD 
therapy, and ventricular assist device (VAD) implantation were obtained from medical records. 
The primary endpoint of this study was all-cause mortality. The secondary endpoint was 
the rate of major adverse cardiac events (MACEs) as an indicator of long-term prognosis. MACE 
was defined as cardiac death, hospital admission for heart failure, appropriate ICD therapy, and 
VAD implantation. Continuous data are presented as means ± SD. Comparison of continuous 
variables was performed using two-sided Student’s t-tests. Categorical data were compared using 
the chi-square test or Fisher’s exact test. All-cause mortality and survival free from MACEs were 
estimated using Kaplan-Meier time-to-event methodology, and patients groups were compared 
using the log-rank test. The risk of developing MACE was estimated by computing hazard ratios 
(HRs) and their 95% confidence intervals (CIs) based on Cox proportional hazards models. Any 
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variable with P <0.05 during univariate analysis was included in a multivariate model to identify 
independent predictors of MACE. P <0.05 was considered to be statistically significant for all 
statistical tests. All statistical analyses were performed using JMP (version 11.0, SAS Inc., Tokyo, 
Japan). 
 
Results 
Data from 534 consecutive patients with ICDs implanted between 2007 and 2012 were 
retrospectively collected. There were 87 patients with ischemic heart disease, 306 with non-
ischemic cardiomyopathy, 21 with valvular heart disease, 10 with congenital heart disease, 85 
with arrhythmias, 11 with vasospastic angina, and 14 with other cardiac diseases. We excluded 
one IHD patient who underwent VAD implantation before ICD implantation and two patients who 
were lost to follow-up. Ultimately, the study population consisted of 84 patients. The patients 
were classified into two groups according to presence of CTO (CTO group, n=34) and absence of 
CTO (non-CTO group, n=50) (Figure 1). Baseline clinical characteristics, medical history, and 
examination data are shown in Table 1. In the CTO group, the mean number of CTOs per patient 
was 1.3 ± 0.5, and 21 (62%) patients had CTO in the left anterior descending (LAD) artery. There 
were no significant differences in the baseline characteristics between the CTO and non-CTO 
groups. 
9 
 
During a median follow-up period of 3.8 years (interquartile range (IQR) 2.7–5.4 years), 
the primary outcome occurred in 20 (23.8%) patients (Table 2). The cumulative event rate for the 
primary outcome, all-cause mortality, was 4.8% at 1 year, 15.8% at 3 years, and 30.3% at 5 years 
of follow-up. Kaplan-Meier analysis revealed that the primary outcome tended to occur more 
frequently in the CTO group than in non-CTO group (log-rank test, P=0.06) (Figure 1). Cox 
proportional hazard regression revealed that the presence of CTO was not significantly related to 
all-cause mortality (unadjusted HR 2.30, 95% CI 0.95–5.88; P=0.06) (Supplemental Table 1). 
During the follow-up period, 47 (56%) patients developed MACE as a secondary endpoint. The 
cumulative incident rate for MACE was 27.4% at 1 year, 54.0% at 3 years, and 62.5% at 5 years 
of follow-up. Kaplan-Meier analysis revealed that the CTO group tended to have a higher MACE 
rate than the non-CTO group (log rank test, P=0.054) (Figure 2). Presence of CTO had a HR of 
1.75 for MACE (95% CI 0.98–3.11; P=0.14) (Supplemental Table 1). 
Baseline characteristics of the primary or secondary prevention subgroups are presented 
in Supplemental Table 2 and Supplemental Table 3, respectively. In the 35 patients receiving 
ICD for primary prevention, there were no significant differences in mortality and MACE rates 
between the CTO and non-CTO groups (Figures 2C and 2D, Tables 2 and Supplemental Table 
4). In the 47 patients receiving ICD as secondary prevention, mortality and MACE rates in the 
CTO group were significantly higher than those in the non-CTO group (Figures 2E and 2F, Table 
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2 and Supplemental Table 5). Among the components of MACE, cardiac death was significantly 
associated with the presence of CTO in the secondary prevention group (Table 2). Cox 
proportional hazards regression analysis showed that the presence of CTO is an independent 
predictive factor for mortality and MACE, whereas LVEF was not. 
We also assessed the viability of the CTO area in the CTO group, which was divided 
into the following two subgroups: CTO with viability (CTO/+viability group, n=21) and CTO 
without viability (CTO/-viability group, n=13). Kaplan-Meier analysis revealed that there was no 
significant difference between these subgroups in all-cause mortality (log-rank test, P=0.16) and 
MACEs (log-rank test, P=0.13) (Figures 3A and 3B). 
Before ICD implantation, revascularization for CTO was performed in 6 patients with 
PCI and 18 with CABG. There was no significant difference in all-cause mortality and MACE 
rates between these 24 patients with CTO revascularization and patients with CTOs who did not 
undergo revascularization (n=22) (HR 0.70; 95% CI 0.23–2.01; P=0.50 and HR 0.80; 95% CI 
0.39–1.63; P=0.80, respectively). 
Discussion 
The major findings of this study are as follows: (1) 40% of patients with IHD and ICD 
implantation had CTO, (2) the CTO group tended to have a higher all-cause mortality and MACE 
rates than the non-CTO group, and (3) in a subgroup of patients with ICD for secondary 
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prevention, the presence of CTO was associated with high mortality and adverse clinical events, 
whereas LVEF was not. 
 
High prevalence of CTO in IHD patients with ICDs 
In previous studies of patients with IHD, there was a range in the prevalence of CTO. The 
CREDO-Kyoto Registry Cohort-2 study showed that 19% of patients (2,491 of 13,087 patients) 
in the PCI arm had CTO.13 Jeroudi et al. reported that the prevalence of CTO was 31% (319 of 
1,015) in patients with coronary artery disease in a tertiary Veterans Affairs Hospital.14 In the 
National Cardiovascular Data Registry CathPCI Registry, the big data of PCI in the United States, 
PCI was performed for CTO in 3.8% of patients (22,365 of 594,510).15 This registry showed that 
the percentage of PCIs for CTO increased from 3.2% in 2009 to 4.8% in 2013. There have been 
two studies in IHD patients with ICD, which showed a CTO prevalence rate of 44% and 69%, 
respectively.16, 17 The present study showed that 40% of IHD patients with ICDs had CTO, which 
is consistent with previous studies. 
Prognostic impact of CTO in IHD patients with ICDs  
The present study showed that the rates of all-cause mortality and MACE were not significantly 
different between the two groups, but they tended to be higher in the CTO group. There have been 
two previous studies regarding the impact of CTO in patients with ICD. However, these studies 
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were limited to patients who received ICD for primary prevention and their results seem to be 
conflicting.16, 17 Nombela-Franco et al. reported that the presence of CTO was significantly 
associated with mortality and ventricular arrhythmias in patients with ICDs implanted for primary 
prevention.16 On the contrary, Raja et al. reported that the presence of CTO was not associated 
with mortality or the incidence of ventricular arrhythmias in patients with ICDs implanted for 
primary prevention.17 In our subgroup analysis, there was no association between the presence of 
CTO and clinical outcomes in patients with ICD for primary prevention. The prevalence of 
previous MI was much higher in our study (99%) and the study by Raja et al. (79%) than the 
study by Nombela-Franco et al. (51%), although LVEF in the three studies were not obviously 
different (Nombela-Franco et al.; 29%, Raja et al. 30%, our study; 25%). The study population in 
our study and the study by Raja et al. might have reflected more selected IHD patients. Another 
explanation of the discrepancy in results in the primary prevention population might be related to 
the prevalence of CKD, a known predictor of prognosis in patients with IHD. 18 In the previous 
two studies, the prevalence of CKD ranged from 27% to 40%. However, in our study, all patients 
in the CTO group and 94% of patients in the non-CTO group had CKD. 
Importantly, to the best of our knowledge, our study revealed for the first time the negative impact 
of CTO on long-term mortality and the MACE rate in IHD patients with ICDs implanted for 
secondary prevention. In patients who received ICD for secondary prevention, the presence of 
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CTO was an independent predictor of all-cause mortality and MACE, while LVEF was not. It 
should be noted that our study population had reduced LV function, with mean LVEF of 24 ± 8%. 
Among these particularly high-risk patients with severe cardiac dysfunction, LVEF might no 
longer be a statistically significant predictor of long-term prognosis. However, the small study 
size might be a limitation. The reason why the presence of CTO affects prognosis only in the 
secondary prevention group of our study should be investigated. Amiodarone was not 
significantly related to mortality and the rate of MACE. This was also the same results when the 
population was limited to the patients with ICD for primary or secondary prevention. In our study, 
there was no significant difference in LVEF between the primary and secondary prevention groups. 
However, the primary prevention group had larger LV end-diastolic and end-systolic diameters 
than the secondary prevention group. There were no differences in clinical characteristics other 
than the prevalence of CRT-D between the two groups (primary prevention group 62% vs. 
secondary prevention group 30%). These findings suggest that LV remodeling was rather 
developed in the primary prevention group and that there must be other confounders impacting 
the prognosis of the secondary prevention group. 
Implications of the present study and revascularization for CTO 
In clinical practice, the importance of revascularization for vessels with CTO that have territories 
with viable myocardium is frequently discussed. In our study, 44% of patients in the CTO group 
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had viable tissue in the CTO area. However, only one patient underwent revascularization with 
PCI. This patient experienced sudden cardiac death without any events 4.1 years after PCI. Our 
study population might have had some characteristics that made them not suitable for PCI or 
CABG, such as CKD, anatomically complex lesions, or small viable area. Another possible reason 
for the low rate of revascularization might be that revascularization with PCI was performed for 
suitable lesions before ICD implantation. Indeed, revascularization for CTO was performed in 24 
patients in this study (6 with PCI and 18 with CABG), but revascularization for CTO had no 
beneficial impact on clinical outcomes. This might be mainly because our sample size was small. 
The STICH trial could not identify patients with differences in survival benefit from CABG based 
on assessment of myocardial viability using single-photon emission computed tomography, 
dobutamine echocardiography, or both.19 Furthermore, studies quantifying ventricular function 
using MRI have shown that the improvement in ventricular function as a result of opening CTOs 
is very modest.8, 20 There was a large multicenter prospective cohort study (IRCTO registry 21) 
showing that the successful rate of CTO PCI was 75.4%, which was consistent with that in other 
studies (ref). In the IRCTO registry study, the patients who underwent PCI for CTO had better 
survival and lower major adverse cardiac and cerebrovascular events compared to those who had 
medical therapy only. However, it is difficult to clarify the effects of PCI to CTO due to the 
variety of patient backgrounds and clinical settings. Also, in the IRCTO registry, the rate of peri-
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procedural complication was not significantly different between the patients with and without 
successful PCI. Because of the improved devices and techniques, CTO PCI is getting safer. 
Consequently, interventionists are now seeking patients with good indications for PCI. Our study 
suggests that the revascularization of CTOs in patients with ICD as secondary prevention may 
provide some benefit. 
 
Study limitations  
There were several limitations in the present study. First, this was a retrospective observational 
study, although the baseline patient characteristics of the two groups were similar. Second, the 
study population was relatively small. The present study was obviously underpowered for 
evaluating long-term clinical outcomes. Third, assessment of myocardial was not performed in all 
patients with CTO. Finally, our findings do not warrant revascularization of CTO in ischemic heart 
disease with ICD. Although hibernating myocardium was associated with arrhythmogenesis in 
animal models 22, it is inevitable to assess myocardial ischemia/viability in the territory of the CTO 
in the previous clinical studies. Further large and randomized studies with standardized evaluation 
of viable myocardium are necessary to elucidate this issue. Furthermore, contemporary 
interventions for CTO including retrograde approach have dramatically improved. However, the 
previous studies of the US and Japanese registries demonstrated that procedural success was 
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associated with several patient factors and operator experience. 23, 24 
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Figure Legends 
Figure 1. Study flow chart 
CTO, chronic total coronary occlusion; ICD, implantable cardioverter-defibrillator; VAD, 
ventricular assist device. 
Figure 2. All-cause mortality and MACE-free survival in all patients (n=84) (A)(B), patients 
with ICD for primary prevention (n=37) (C)(D), and in patients with ICD for secondary 
prevention (n=47) (E)(F). 
MACE includes cardiac death, appropriate device therapy, hospitalization due to heart failure, 
and ventricular assist device implantation. The data of the CTO and non-CTO groups were 
compared. MACE, major adverse cardiac event. 
Figure 3. Kaplan-Meier analysis of all-cause mortality (A) and MACE-free survival (B) in 
patients with CTO by myocardial viability. 
The viability of the myocardium in the CTO area was determined by the presence of radionuclide 
uptake on myocardial scintigraphy, or the absence of a thinned scar, dyskinesis, or left ventricular 
wall thinning on echocardiography. 
  
18 
 
References 
1. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic 
implantation of a defibrillator in patients with myocardial infarction and reduced 
ejection fraction. N Engl J Med. 2002;346:877-83. 
2. Kuck KH, Cappato R, Siebels J and Ruppel R. Randomized comparison of 
antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from 
cardiac arrest : the Cardiac Arrest Study Hamburg (CASH). Circulation. 2000;102:748-
54. 
3. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and 
the prevention of sudden cardiac death: The Task Force for the Management of Patients 
with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the 
European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric 
and Congenital Cardiology (AEPC). Europace. 2015;17:1601-87. 
4. Guidelines for Non-Pharmacotherapy of Cardiac Arrhythmias (JCS 2011). Circulation 
journal : official journal of the Japanese Circulation Society. 2013;77:249-74. 
5. Veenhuyzen GD, Singh SN, McAreavey D, Shelton BJ and Exner DV. Prior coronary 
artery bypass surgery and risk of death among patients with ischemic left ventricular 
19 
 
dysfunction. Circulation. 2001;104:1489-93. 
6. Allman KC, Shaw LJ, Hachamovitch R and Udelson JE. Myocardial viability testing and 
impact of revascularization on prognosis in patients with coronary artery disease and left 
ventricular dysfunction: a meta-analysis. Journal of the American College of Cardiology. 
2002;39:1151-8. 
7. Noguchi T, Miyazaki MS, Morii I, Daikoku S, Goto Y and Nonogi H. Percutaneous 
transluminal coronary angioplasty of chronic total occlusions. Determinants of primary 
success and long-term clinical outcome. Catheterization and cardiovascular 
interventions : official journal of the Society for Cardiac Angiography & Interventions. 
2000;49:258-64. 
8. Kirschbaum SW, Baks T, van den Ent M, Sianos G, Krestin GP, Serruys PW, et al. 
Evaluation of left ventricular function three years after percutaneous recanalization of 
chronic total coronary occlusions. The American journal of cardiology. 2008;101:179-
85. 
9. Shaw LJ, Berman DS, Maron DJ, Mancini GB, Hayes SW, Hartigan PM, et al. Optimal 
medical therapy with or without percutaneous coronary intervention to reduce ischemic 
burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive 
Drug Evaluation (COURAGE) trial nuclear substudy. Circulation. 2008;117:1283-91. 
20 
 
10. Cwajg JM, Cwajg E, Nagueh SF, He ZX, Qureshi U, Olmos LI, et al. End-diastolic wall 
thickness as a predictor of recovery of function in myocardial hibernation: relation to 
rest-redistribution T1-201 tomography and dobutamine stress echocardiography. Journal 
of the American College of Cardiology. 2000;35:1152-61. 
11. Bonow RO, Dilsizian V, Cuocolo A and Bacharach SL. Identification of viable 
myocardium in patients with chronic coronary artery disease and left ventricular 
dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging 
with 18F-fluorodeoxyglucose. Circulation. 1991;83:26-37. 
12. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, et al. Modification of the 
Modification of Diet in Renal Disease (MDRD) Study equation for Japan. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 
2007;50:927-37. 
13. Yamamoto E, Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Ono K, et al. Long-
term outcomes after percutaneous coronary intervention for chronic total occlusion (from 
the CREDO-Kyoto registry cohort-2). The American journal of cardiology. 
2013;112:767-74. 
14. Jeroudi OM, Alomar ME, Michael TT, El Sabbagh A, Patel VG, Mogabgab O, et al. 
Prevalence and management of coronary chronic total occlusions in a tertiary Veterans 
21 
 
Affairs hospital. Catheterization and cardiovascular interventions : official journal of 
the Society for Cardiac Angiography & Interventions. 2014;84:637-43. 
15. Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, et al. 
Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a 
report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovascular 
interventions. 2015;8:245-53. 
16. Nombela-Franco L, Mitroi CD, Fernandez-Lozano I, Garcia-Touchard A, Toquero J, 
Castro-Urda V, et al. Ventricular arrhythmias among implantable cardioverter-
defibrillator recipients for primary prevention: impact of chronic total coronary 
occlusion (VACTO Primary Study). Circ Arrhythm Electrophysiol. 2012;5:147-54. 
17. Raja V, Wiegn P, Obel O, Christakopoulos G, Christopoulos G, Rangan BV, et al. Impact 
of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and 
the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. 
The American journal of cardiology. 2015;116:1358-62. 
18. Go AS, Chertow GM, Fan D, McCulloch CE and Hsu CY. Chronic kidney disease and 
the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 
2004;351:1296-305. 
19. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. 
22 
 
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 
2011;364:1617-25. 
20. Werner GS, Surber R, Kuethe F, Emig U, Schwarz G, Bahrmann P, et al. Collaterals and 
the recovery of left ventricular function after recanalization of a chronic total coronary 
occlusion. American heart journal. 2005;149:129-37. 
21. Tomasello SD, Boukhris M, Giubilato S, Marza F, Garbo R, Contegiacomo G, et al. 
Management strategies in patients affected by chronic total occlusion: results from the 
Italian Registry of Chronic Total Occlusions. Eur Heart J.  2015;36:3189-98. 
22. John M. Canty, Jr, Gen Suzuki, Michael D. Banas, Fons Verheyen, Marcel Borgers, 
James A. Fallavollita. Hibernating myocardium: chronically adapted to ischemia but 
vulnerable to sudden death. Circ Res. 2004;94:1142-1149. 
23. Brilakis ES, Banerjee S, Karmpaliotis D, Lombardi WL, Tsai TT, Shunk KA, et al. 
Procedural outcomes of chronic total occlusion percutaneous coronary intervention: a 
report from the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc 
Interv. 2015;8:245-53. 
24. Habara M, Tsuchikane E, Muramatsu T, Kashima Y, Okamura A, Yamane M , et al. 
Comparison of percutaneous coronary intervention for chronic total occlusion outcome 
according to operator experience from the Japanese retrograde summit registry. Catheter 
23 
 
Cardiovasc Interv. 2016;87:1027-35. 



Table 1. Baseline characteristics of patients by CTO status  
  
All patients 
(n=84) 
CTO 
(n=34) 
Non-CTO  
(n=50) 
P value 
Age (years) 70 ± 8 71 ± 1 69 ± 1 0.90  
Male 72 (86) 32 (94) 40 (80) 0.11  
Body mass index (kg/m2) 22 ± 3 22 ± 1 22 ± 1 0.42  
CRT-D 37 (44) 17 (50) 20 (40) 0.36  
ICD for secondary prevention 47 (56) 16 (47) 31 (62) 0.18  
NYHA functional class ≥3 26 (31) 12 (35) 14 (28) 0.48  
Diabetes mellitus 38 (45) 15 (44) 23 (46) 0.86  
Hypertension 59 (70) 24 (71) 35 (70) 0.95  
Dyslipidaemia 62 (74) 24 (71) 38 (76) 0.58  
Current smoking 15 (18) 7 (21) 8 (16) 0.59  
Chronic kidney disease 81 (96) 34 (100) 47 (94) 0.29  
Previous myocardial infarction 83 (99) 33 (97) 50 (100) 0.40  
Multivessels disease 70 (83) 31 (91) 39 (78) 0.14  
Previous CABG 34 (40) 13 (38) 21 (42) 0.73  
Previous PCI 62 (74) 24 (71) 38 (76) 0.58  
QRS width (msec) 142 ± 29 142 ± 5 143 ± 4 0.39  
Chronic AF 17 (20) 10 (29) 7 (14) 0.08  
History of non-sustained VT 73 (87) 29 (85) 44 (88) 0.75  
LV end diastolic diameter (mm) 65 ± 9 66 ± 2 64 ± 1 0.73  
LV end systolic diameter (mm) 55 ± 11 57 ± 2 54 ± 2 0.86  
LVEF (%) 24 ± 8 23 ± 1 25 ± 1 0.13  
Mitral regurgitation ≥grade 3 13 (15) 5 (15) 8 (16) 1.00  
β-blocker 69 (82) 27 (79) 42 (84) 0.59  
ACE-I or ARB 57 (68) 21 (62) 36 (72) 0.32  
Statin 61 (73) 21 (62) 40 (80) 0.07  
Oral inotropes 13 (15) 7 (14) 6 (18) 0.65  
Amiodarone 44 (52) 17 (50) 27 (54) 0.72  
No. of CTOs/case (/patient) - 1.3 ± 0.5 - - 
CTO in LAD - 21 (62) - - 
Viability in CTO area - 15 (44) - - 
Data are presented as means ± SD, n (%), or medians (interquartile range). P values are for CTO group 
vs. non-CTO group. CTO, chronic total coronary occlusion; CRT-D, cardiac resynchronization 
therapy-defibrillator; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart 
Association; CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; AF, 
atrial fibrillation; VT, ventricular tachycardia; LV, left ventricular; EF, ejection fraction; ACE-I, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; LAD, left anterior 
descending artery. 
 
  
Table 2. Follow-up event rates for all patients and by prevention subgroup  
  
All patients 
(n=84) 
Patients with ICD for primary prevention 
(n=37) 
Patients with ICD for secondary prevention 
(n=47) 
  CTO group Non-CTO group P value CTO group Non-CTO group P value CTO group Non-CTO group P value 
All-cause mortality 12 (35.3%) 8 (16%) 0.07 4 (22.2%) 4 (21.1%) 1.00 8 (50.0%) 4 (12.9%) 0.01 
MACE 23 (67.6%) 24 (48%) 0.12 11 (61.1%) 9 (47.4%) 0.51 12 (75.0%) 15 (48.4%) 0.12 
  Cardiac death 10 (29.4%) 6 (12%) 0.05 3 (16.7%) 3 (15.8%) 1.00 7 (43.8%) 3 (9.7%) 0.02 
  Appropriate ICD therapy 13 (38.2%) 12 (24%) 0.22 5 (27.8%) 2 (10.5%) 0.23 8 (50.0%) 10 (32.3%) 0.34 
  Hospital admission for heart failure 16 (47.1%) 17 (34%) 0.26 8 (44.4%) 8 (42.1%) 1.00 8 (50.0%) 9 (29.0%) 0.21 
  Ventricular assist device implantation 0 (0%) 1 (2%) 1.00 0 (0%) 1 (5.3%) 1.00 0 (0%) 0 (0%) - 
 
MACE, major adverse cardiovascular events. Other abbreviations as in Table 1. 
 
Table 3. Univariate and multivariate analysis of predictors of all-cause mortality and MACE  
Variable All patients (n=84) 
 All-cause mortality  MACE 
 Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
  HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
CTO 2.30 (0.95-5.88)  0.06  1.79 (0.71-4.72)  0.22 1.75 (0.98-3.11)  0.06  1.56 (0.86-2.82)  0.14 
Age (per one-year increase) 1.02 (0.97-1.09)  0.44      1.01 (0.98-1.05)  0.51      
Male 3.27 (0.68-58.7)  0.16      1.20 (0.55-3.15)  0.67      
CRT-D 0.91 (0.36-2.22)  0.85      1.28 (0.72-2.27)  0.40      
Secondary prevention 1.21 (0.50-3.10)  0.67      1.10 (0.62-2.00)  0.74     
NYHA functional class ≥3 2.81 (1.15-6.87)  0.02  2.31 (0.92-5.78)  0.07 2.50 (1.37-4.48) < 0.01  2.32 (1.15-4.69)  0.02 
Diabetes mellitus 0.97 (0.39-2.34)  0.94      1.18 (0.66-2.11)  0.56      
Hypertension 0.55 (0.23-1.40)  0.20      0.73 (0.40-1.36)  0.31      
Dyslipidaemia 0.86 (0.34-2.43)  0.76      1.32 (0.69-2.72)  0.41      
Current smoking 0.68 (0.16-2.03)  0.52      1.20 (0.54-2.39)  0.63      
Multivessel disease 0.17 (0.39-5.03)  0.80      1.55 (0.71-4.06)  0.29      
LVEF 0.97 (0.92-1.02)  0.28      0.96 (0.92-0.99)  0.02  0.98 (0.93-1.02)  0.23 
Mitral regurgitation ≥grade 3 1.22 (0.35-3.35)  0.72      1.68 (0.79-3.25)  0.17      
β-blocker 0.45 (0.17-1.40)  0.15      0.46 (0.24-0.95)  0.04  0.37 (0.18-0.81)  0.01 
Amiodarone 1.86 (0.76-4.96)  0.17     1.56 (0.88-2.84)  0.13     
Statin 0.36 (0.15-0.91)  0.03  0.47 (0.19-1.24)  0.13 1.31 (0.69-2.70)  0.43      
ACE-I or ARB 0.46 (0.19-1.13)   0.09        0.53 (0.30-0.97)   0.04  0.69 (0.38-1.31)   0.25 
Abbreviations as in Table 1.  
Table 4. Baseline characteristics of patients with ICD implantation for secondary prevention  
  Secondary prevention (n=47) 
  
CTO 
(n =16) 
Non-CTO  
(n =31) 
P value 
Age (years) 73 ± 9 69 ± 8 0.17 
Male 15 (94) 23 (74) 0.14 
Body mass index (kg/m2) 22 ± 3 22 ± 4 0.55 
CRT-D 5 (31) 9 (29) 1.00 
NYHA functional class ≥3 6 (38) 7 (23) 0.32 
Diabetes mellitus 6 (38) 12 (40) 1.00 
Hypertension 20 (65) 20 (65) 1.00 
Dyslipidaemia 13 (81) 22 (71) 0.51 
Current smoking 6 (19) 6 (19) 1.00 
Chronic kidney disease 29 (94) 29 (94) 0.54 
Previous myocardial infarction 16 (100) 31 (100) - 
Multivessel disease 14 (88) 25 (81) 0.70 
Previous CABG 4 (25) 13 (42) 0.34 
Previous PCI 13 (81) 21 (68) 0.49 
QRS width 137 ± 29 142 ± 33 0.61 
Chronic AF 4 (25) 3 (10) 0.21 
History of non-sustained VT 16 (100) 31 (100) - 
LV end diastolic diameter (mm) 63 ± 13 63 ± 8 0.86 
LV end systolic diameter (mm) 56 ± 14 51 ± 10 0.25 
LVEF (%) 21 ± 7 25 ± 7 0.09 
Mitral regurgitation ≥grade 3 4 (25) 5 (16) 0.47 
β-blocker 12 (80) 27 (90) 0.21 
ACE-I or ARB 6 (38) 22 (71) 0.03 
Statin 11 (69) 24 (77) 0.73 
Oral inotropes 3 (19) 1 (3) 0.11 
Amiodarone 11 (69) 18 (58) 0.54 
No. of CTOs/case (/patient) 1.1 ± 0.3 -  
CTO in LAD 9 (56) -  
Viability in CTO area 8 (50) -   
Abbreviations as in Table 1.  
  
Table 5. Univariate and multivariate analysis of predictors of all-cause mortality and MACE in patients who received ICD for secondary prevention 
variable Secondary prevention group (n=47) 
 All-cause mortality MACE 
 Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
  HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
CTO 4.69 (1.47–17.7)   0.01  3.70 (1.12–14.3)   0.03 2.86 (1.27–6.41)   0.01  2.59 (1.10–5.93)   0.03 
Age (years) 1.09 (1.00–1.18)  0.04  1.06 (0.98–1.16)  0.16 1.02 (0.98–1.07)  0.38      
Male 3.02 (0.59–555)  0.22      1.14 (0.47–3.40)  0.79      
CRT-D 0.88 (0.19–2.97)  0.22      1.36 (0.58–3.00)  0.46      
NYHA functional class ≥3 1.51 (0.40–4.83)  0.51      2.23 (0.98–4.84)  0.06      
Diabetes mellitus 1.86 (0.59–6.29)  0.29      2.25 (1.05–4.92)  0.04  2.41 (1.09–5.45)  0.03 
Hypertension 1.06 (0.33–3.96)  0.76      1.11 (0.51–2.59)  0.80      
Dyslipidaemia 0.82 (0.26–3.09)  0.76      1.68 (0.71–4.65)  0.25      
Current smoking 0.30 (0.02–1.56)  0.18      0.91 (0.30–2.26)  0.86      
Multivessel disease 1.25 (0.33–8.17)  0.77      2.25 (0.78–9.50)  0.14      
LVEF 1.03 (0.95–1.11)  0.50      0.97 (0.92–1.02)  0.24      
Mitral regurgitation ≥grade 3 1.34 (0.30–4.50)  0.67      2.25 (0.92–1.02)  0.07      
β-blocker 0.35 (0.10–1.59)  0.15      0.27 (0.11–0.67)  0.02  0.34 (0.13–0.95)  0.04 
Amiodarone 1.92 (0.57-8.67)  0.31     1.33 (0.61-3.10)  0.48     
statin 0.33 (0.10–1.06)  0.06      1.51 (0.64–4.12)  0.36      
ACE-I or ARB 0.33 (0.09–1.06)   0.06          0.52 (0.24–1.12)   0.09          
Abbreviations as in Table 1.  
 
SUPPLEMENTAL MATERIAL 
Supplemental Table 1. Baseline characteristics of patients with ICD implantation for primary prevention  
  Primary prevention (n=37) 
 
CTO 
(n =18) 
Non-CTO 
(n =19) 
P value 
Age (years) 70 ± 7 68 ± 9 0.58 
Male 17 (94) 17 (89) 1.00 
Body mass index (kg/m2) 23 ± 3 23 ± 4 0.84 
CRT-D 12 (67) 11 (58) 0.74 
NYHA functional class ≥3 6 (33) 7 (37) 1.00 
Diabetes mellitus 9 (50) 10 (53) 1.00 
Hypertension 13 (72) 15 (79) 0.71 
Dyslipidaemia 11 (61) 16 (84) 0.15 
Current smoking 4 (22) 2 (11) 0.40 
Chronic kidney disease 18 (100) 18 (95) 1.00 
Previous myocardial infarction 17 (94) 19 (100) 0.49 
Multivessel disease 17 (94) 14 (74) 0.18 
Previous CABG 9 (50) 8 (42) 0.75 
Previous PCI 11 (61) 17 (89) 0.06 
QRS width 145 ± 30 145 ± 22 0.99 
Chronic AF 6 (33) 4 (21) 0.48 
History of non-sustained VT 13 (72) 13 (68) 1.00 
LV end diastolic diameter (mm) 68 ± 2 67 ± 2 0.80 
LV end systolic diameter (mm) 58 ± 2 58 ± 2 0,92 
LVEF (%) 24 ± 8 25 ± 11 0,83 
Mitral regurgitation ≥grade 3 1 (6) 3 (16) 0.60 
β-blocker 15 (83) 14 (74) 0.69 
ACE-I or ARB 15 (83) 14 (74) 0.69 
Statin 10 (56) 16 (84) 0.08 
Oral inotropes 3 (17) 6 (32) 0.45 
Amiodarone 6 (33) 9 (47) 0.51 
No. of CTOs/case (/patient) 1.2 ± 0.4 -  
CTO in LAD 12 (67) -  
Viability in CTO area 7 (39) -   
Abbreviations as in Table 1.  
  
Supplemental Table 2. Univariate and multivariate analysis of predictors of all-cause mortality and MACE in patients who received ICD for primary prevention 
Variable Primary prevention group (n=37) 
 All-cause mortality MACE 
 Univariate analysis Multivariate analysis Univariate analysis Multivariate analysis 
 HR  (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
CTO 0.95   (0.22–4.02)   0.94  0.47   (0.07–2.47)   0.38  1.22   (0.50–3.07)   0.66  1.27   (0.52–3.16)   0.60  
Age (years) 0.94   (0.88–1.03)  0.18      0.99  (0.94–1.06)  0.80      
Male NA        1.71  (0.35–30.8)  0.54      
CRT-D 1.11   (0.27–5.44)  0.88      1.34  (0.54–3.79)  0.54      
NYHA functional class ≥3 7.43   (1.70–50.9) < 0.01  4.12   (0.60–46.9)  0.16 2.78  (1.12–6.92)  0.03  2.82   (1.13–7.03)  0.03 
Diabetes mellitus 0.35   (0.05–1.53)  0.17      0.53  (0.21–1.29)  0.16      
Hypertension 0.20   (0.05–0.86)  0.03  0.20   (0.04–1.04)  0.06 2.36  (0.17–1.13)  0.08      
Dyslipidaemia 0.94   (0.21–6.44)  0.94      1.21  (0.47–3.73)  0.70      
Current smoking 1.45   (0.21–6.33)   0.66      1.59  (0.45–4.33)  0.43      
Multivessel disease 1.10   (0.19–20.7)  0.93      1.05  (0.35–4.52)  0.93      
LVEF 0.91   (0.82–0.99)  0.03  0.95   (0.83–1.08)  0.45 0.95  (0.90–1.00)  0.06      
Mitral regurgitation ≥grade 3 0.94   (0.05–5.31)  0.95      0.86  (0.14–3.00)  0.84      
β-blocker 0.58   (0.13–3.99)  0.53      0.64  (0.25–1.97)  0.40      
Amiodarone 1.67  (0.39-7.09)  0.47     1.77 (0.72-4.33)  0.21     
Statin 0.43   (0.10–2.27)  0.28      1.24  (0.48–3.82)  0.67      
ACE-I or ARB 0.83   (0.19–5.69)   0.83          0.59  (0.23–1.82)   0.33          
Abbreviations as in Table 1.  
 
